RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression

Cho, Hee Jun; Baek, Kyoung Eun; Park, Sun-Mi; Kim, In Kyu; Nam, In-Koo; Choi, Young-Ho; Park, Seung-Ho; Im, Min-Ju; Choi, Jungil; Ryu, Jinhyun; Kim, Jae Won; Lee, Chang Won; Kang, Sang Soo; Yoo, Ji Myong

doi:10.1016/j.canlet.2011.06.024

Cited by 36 publications

(44 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike bladder cancer and lymphoma cells, RhoGDI2 was reported as an oncogene in breast, colon and gastric cancer cells (9,10,24). A Korean group reported that RhoGDI2 confers resistance to cisplatin-induced apoptosis in gastric cancer cells by upregulating Bcl-2 expression and activating PLCγ (19,25). Our results also demonstrated that RhoGDI2 is involved in the resistance to 5-FU in gastric cancer cells.…”

Section: Discussionsupporting

confidence: 70%

“…However, Lee et al (18) recently revealed contradictory results suggesting that the chemo-resistance in ovarian serous carcinomas is associated with the downregulation of RhoGDI2 expression. Hee et al (19) reported that RhoGDI2 confers resistance against cisplatin-induced apoptosis in gastric cancer cells. The results of the current study lead to the conclusion that high levels of RhoGDI2 expression are associated with chemotherapy resistance in certain types of cancers, including gastroenterological cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells

Zheng

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. Resistance to 5-fluorouracil (5-FU) in patients with gastric cancer is a serious therapeutic problem and major efforts are underway to understand the underlying mechanisms. We have previously identified RhoGDI2 as a contributor to 5-FU resistance in colon cancer cells using 2D electrophoresis and mass spectrometry and the current study aimed to further investigate this role. The expression of RhoGDI2 in seven gastric cancer cell lines was positively correlated with resistance to 5-FU. Lower 5-FU sensitivity of isolated tumor cells from patients with gastric cancer was also associated with higher RhoGDI2 expression. Ectopic expression of RhoGDI2 in gastric cancer cells increased the resistance to 5-FU and reverted low dose 5-FU-induced G2/M phase arrest without affecting the population of sub-G1 cells. Overall, these findings suggest that RhoGDI2 is associated with 5-FU resistance and is a potential therapeutic target for enhancing chemotherapy efficacy in gastric cancer.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells

Zheng

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…ROCK inhibitor-induced apoptosis was shown to be Bcl-2 sensitive, and Bcl-2 families are known to affect cell apoptosis by regulating the permeability of mitochondria [34,35]. In addition, fasudil [20].…”

Section: Discussionmentioning

confidence: 97%

The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells

Takeba

Matsumoto

Watanabe

et al. 2012

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…There is reverse correlation between PDCD5 and Bcl-2 expression in gastric cancer tissues [6]. Furthermore, silencing Bcl-2 mRNA expression could enhance chemotherapeutic effects in the treatment of gastric cancer by cisplatin [26], and upregulation of Bcl-2 expression confers gastric cancer cells resistance against cisplatin-induced apoptosis [27]. Further study is needed to confirm whether Bcl-2 expression is decreased by PDCD5 transfection and underlies the enhanced sensitivity to cisplatin in gastric cancer cells.…”

Section: Discussionmentioning

confidence: 97%